Page 8 - Sun Pharma

Investment idea: Motilal Oswal bullish on Sun Pharma; check outlook, upside

Sun Pharma, the brokerage said, is building an interesting specialty pipeline (under development) for addressing patient's needs in areas of dermatology, ophthalmology, and onco-dermatology

Sun Pharma slips 3% after OAI status from USFDA for Dadra facility

In an exchange filing Sun Pharma said, the US Food and Drug Administration (US FDA) conducted an inspection at the company's Dadra facility from December 4, 2023 to December 15, 2023

Sun Pharma gets approval to sell acne treatment cream Winlevi in Australia

Collaboration with Cosmo enables rights for cream in several countries, says company

Sun Pharma gets regulatory nod in Australia for acne treatment cream

Sun Pharmaceutical Industries Ltd on Tuesday said the Australian Therapeutic Goods Administration has granted regulatory approval for Winlevi cream indicated for the topical treatment of acne. The approval is for Winlevi (clascoterone cream 1 per cent), which is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older, the company said in a statement. Sun Pharma received the exclusive right to develop and commercialise Winlevi in the US, Japan, Australia, New Zealand, Brazil, Mexico, and Russia from Cosmo, it added. "Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi's novel mechanism of action will be a welcome addition to the physician's toolkit while treating acne," Hellen de Kloet, Business Head, Western Europe, Australia and New Zealand, Sun Pharma, said. The company said Winlevi will be available in Australia this June. "This is another achievement in the mission of Cosmo and

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Brokerages administer confidence boost, elevating EPS forecasts and target prices for 2024-25

Sun Pharma recalls 55,000 bottles of generic drug to treat gout from US mkt

Drug major Sun Pharma is recalling around 55,000 bottles of a generic medication to treat gout from the American market due to manufacturing practices norms deviations, according to the US health regulator. The New Jersey-based unit of the Mumbai-based drug major is recalling Febuxostat Tablets in 40 mg and 80 mg strengths, US Food and Drug Administration (USFDA) said in its latest Enforcement Report. Sun Pharmaceutical Industries Inc is recalling 47,520 bottles (40mg) and 7,488 bottles (80 mg) respectively of the medication due to Current Good Manufacturing Practice regulations (CGMP) deviations, it stated. "Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment," the USFDA stated. The affected lot was produced at Sun Pharma's Dadra-based plant for Memphis-based Northstar Rx LLC, the US regulator noted. Febuxostat is used to lower uric acid levels in people with gout. As per the USFDA, the company has initiated the Class II nationwide (

Sun Pharma recalls around 55,000 bottles of generic medication in US

Sun Pharma is recalling about 55,000 bottles of a generic medication to treat bowel disease in the American market, according to the US Food & Drug Administration (USFDA). As per the latest Enforcement Report by the US health regulator, New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the Mumbai-headquartered drug major, is recalling 54,960 bottles of Mesalamine extended-release capsules in the American market. Mesalamine delayed-release capsules are indicated for the treatment of mild to moderate ulcerative colitis. The affected lot of capsules have been manufactured by Sun Pharmaceutical Industries at its Mohali-based manufacturing plant and distributed in the US market by Sun Pharmaceutical Industries Inc. As per the USFDA, the company has initiated the Class II recall due to "Failed Dissolution Specifications". The company initiated the Class II recall on February 5 this year. As per the USFDA, a class II recall is initiated in a situation in which the use of, or

Sun Pharma to acquire 16.33% stake in Surgimatix for $3.05 million

Sun Pharmaceutical Industries Ltd on Tuesday said it will acquire a 16.33 per cent stake in Surgimatix, Inc, a US-based firm for USD 3.05 million (over Rs 25 crore). Surgimatix is engaged in the business of developing a proprietary soft tissue fixation device for laparoscopic hernia repair and other minimally invasive surgeries. It is yet to commence its commercial operations, Sun Pharmaceutical Industries said in a regulatory filing. The company has entered into an agreement with Surgimatix, Inc under which it has agreed to acquire 16.33 per cent shares of the latter, additionally, with the right to receive warrants equal to 20 per cent of shares purchased, it added. The cost of acquisition is USD 3.05 million, the filing said, adding that the acquisition is expected to be completed by February 2024, subject to fulfilment of certain conditions. Surgimatix was incorporated on November 19, 2007.

Sun Pharma to acquire 16.33% stake in US-based Surgimatix for $3 million

The transaction is expected to be completed by the end of February 2024, pending fulfilment of certain conditions

NTPC, Gail: How to trade these 5 stocks that turned ex-dividend this week?

As many as 49 stocks turned ex-dividend on the bourses this week. Here's a quick chart check on select five among them.

Market resilience in a pill: Pharma's formula for Q3 earnings upgrades

Rx for returns: Pharma firms' dominance in market recovery prescription

Sun Pharma Q3 results: Net profit up 16.5% at Rs 2,524 cr on US, India biz

Bloomberg analysts' estimates had pegged the revenue at Rs 12,336 crore and PAT at Rs 2,470 crore

Sun Pharma Q3 results: Net profit increases 15% at Rs 2,524 crore

Sales in its US formulations business rose nearly 15 per cent to Rs 3,974 crore, while sales from its India formulations rose more than 11 per cent to Rs 3,779 crore

Sun Pharma to acquire remaining stake in Israeli firm Taro for Rs 2,892 cr

Merger would pave the way for Sun to consolidate its position in the US market, say analysts

Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 mn

The Indian drugmaker, which currently owns about 78.5 per cent stake in Taro, had offered to buy its remaining stake for $38 per share in May

Sun Pharma, Bayer partner for diabetes-linked kidney disease medicine

Diabetes is an epidemic in India, with nearly 100 million Indians suffering from it. Diabetes has also been identified as the leading cause of chronic kidney disease in India

Stocks to Watch: Nestle, Zee Ent, Apollo Tyres, Sun Pharma, JTL Ind, NHPC

Stocks to Watch on December 19, 2023: Nestle set Jan 5 as the record date for its stock-split; Sony India is unlikely to extend the timeline for its merger with Zee Entertainment, reported Livemint

Sun Pharma to acquire 16.7% stake in Lyndra Therapeutics for $30 mn

Sun Pharmaceutical Industries Ltd on Monday said it will acquire a 16.7 per cent stake in US-based Lyndra Therapeutics, Inc for USD 30 million (nearly Rs 250 crore). The company has entered into an agreement to acquire 16.7 per cent shares on a fully diluted basis, in Lyndra Therapeutics Inc, based in Massachusetts, engaged in the business of developing novel delivery technology for long-acting oral (LAO) therapies, Sun Pharmaceutical Industries said in a regulatory filing. On the reasons for the acquisition, Sun Pharma said it is a strategic investment to support the development of innovative pharmaceutical delivery technologies and get access to the technology for certain molecules and territories. The cost of acquisition is USD 30 million and the transaction is expected to be completed by the end of December 2023, subject to certain conditions, it added. Incorporated on January 14, 2015, Lyndra Therapeutics clocked a turnover of USD 10.7 million in 2022, USD 13.1 million in 2021

Stocks to Watch today: Zee, Sun Pharma, Lupin, NTPC, PCBL, Care Ratings

Stocks to watch on Monday, December 18, 2023: Shares of Zee Entertainment are likely to be in focus as company seeks an extension to complete the proposed merger with Sony India.

Sun Pharma, Lupin recall drugs in US market over manufacturing issues: FDA

Leading drugmakers Sun Pharma and Lupin are recalling products in the US market over manufacturing issues, as per the US Food and Drug Administration (USFDA). Mumbai-based Sun Pharmaceutical Industries is recalling 96,192 bottles of Liothyronine Sodium Tablets in the US that are used to treat an underactive thyroid, according to the latest enforcement report issued by the American health regulator. Princeton-based Sun Pharmaceutical Industries Inc, a unit of the company, is recalling the affected lot that was produced at the drugmaker's Dadra-based facility. The company is recalling the lot due to "failed impurities/degradation specifications", the USFDA stated. The company commenced the voluntary nationwide Class II recall on December 4, this year. USFDA stated that Mumbai-based Lupin is also recalling an unspecified number of penicillamine tablets in the US. The medication is used to treat rheumatoid arthritis and Wilson's disease. Baltimore-based Lupin Pharmaceuticals Inc, a u